Does BRENTUXIMAB VEDOTIN Cause Second primary malignancy? 50 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 50 reports of Second primary malignancy have been filed in association with BRENTUXIMAB VEDOTIN (ADCETRIS). This represents 0.5% of all adverse event reports for BRENTUXIMAB VEDOTIN.
50
Reports of Second primary malignancy with BRENTUXIMAB VEDOTIN
0.5%
of all BRENTUXIMAB VEDOTIN reports
33
Deaths
29
Hospitalizations
How Dangerous Is Second primary malignancy From BRENTUXIMAB VEDOTIN?
Of the 50 reports, 33 (66.0%) resulted in death, 29 (58.0%) required hospitalization, and 2 (4.0%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for BRENTUXIMAB VEDOTIN. However, 50 reports have been filed with the FAERS database.
What Other Side Effects Does BRENTUXIMAB VEDOTIN Cause?
Off label use (1,370)
Neuropathy peripheral (695)
Pyrexia (693)
Febrile neutropenia (684)
Death (602)
Neutropenia (561)
Hodgkin's disease (512)
Nausea (392)
Diarrhoea (385)
Anaemia (374)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which BRENTUXIMAB VEDOTIN Alternatives Have Lower Second primary malignancy Risk?
BRENTUXIMAB VEDOTIN vs BREO ELLIPTA
BRENTUXIMAB VEDOTIN vs BREXANOLONE
BRENTUXIMAB VEDOTIN vs BREXPIPRAZOLE
BRENTUXIMAB VEDOTIN vs BREXUCABTAGENE AUTOLEUCEL
BRENTUXIMAB VEDOTIN vs BRIGATINIB